Bet against BSX on this ruling: the preliminary injunction denial opens the door for Stryker's OptaBlate to compete in the BVN ablation market, eroding BSX's current monopoly position (Relievant Medsystems' Intracept product). However, historical performance on BSX signals is very poor (avg T+20 -16.60%), so size positions conservatively and consider that some competitive risk may have been discounted. Watch for the upcoming claim construction hearing and any settlement developments. Stryker shares may see a modest positive reaction from removed near-term launch risk.
Price Chart
Executive Summary
The Federal Circuit affirmed the District of New Jersey's denial of Boston Scientific's (BSX) motion for a preliminary injunction that would have blocked Stryker (SYK) from launching its OptaBlate BVN device. The appeals court found substantial questions regarding whether Stryker induces infringement of BSX's '166 patent, specifically whether the accused device's access cannula 'reaches' the cancellous bone as required. The ruling clears a near-term competitive threat to Stryker but keeps the underlying patent case alive for a full trial on the merits.
Court Ruling Details
Key Facts
- Federal Circuit affirmed denial of preliminary injunction against Stryker's OptaBlate BVN device.
- Court held there are substantial questions of fact regarding whether Stryker induces infringement of claims 16 and 21 of U.S. Patent No. 12,303,166.
- District court's tentative claim construction that 'reaches' means 'touches or extends to' the cancellous bone was not an abuse of discretion.
- Evidence of Stryker's physician instructions was ambiguous — slides, imaging, and IFU diagrams did not clearly show direct infringement.
- Doctrine of equivalents argument was forfeited below and insufficiently supported; conflicting expert testimony raised substantial questions.
- District court has a claim construction hearing scheduled for further proceedings; the case will continue on the merits.
- Pre-filing news discount likely applies — Stryker had announced FDA clearance and plans to market OptaBlate BVN before the filing, so some market impact may be priced in.
- Historical calibration on BSX shows poor prior signal performance (avg call P&L T+20 -16.60%, 0% win rate) — caution warranted on score magnitude.
Financial Impact
Lost opportunity to block a competing product (OptaBlate BVN) in the basivertebral nerve ablation market; no damages awarded or financial figures stated in the ruling.
Risk Factors
- BSX could still win at trial or on a revised claim construction — full merits phase remains.
- Stryker's OptaBlate launch may be delayed by other regulatory or manufacturing issues.
- Appeal to SCOTUS is unlikely given nonprecedential Federal Circuit affirmance.
- Market may have already priced in competitive launch risk — diminished incremental impact.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-1agfa85l-BSX |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 4w ago | Court Ruling | $48.30 $43.88 | ▼ −9.15% | ▼ −8.96% | $42.45 (−12.11%) |
Aug 26, 2026 5w ago | 8-K | $48.17 $43.72 | ▲ +9.24% | ▲ +10.44% | $42.45 (+11.87%) |
Aug 22, 2026 5w ago | Institutional Cluster | $49.01 $44.92 | ▼ −8.35% | ▼ −9.66% | $42.45 (−13.39%) |
Aug 7, 2026 8w ago | Insider Cluster | $49.31 $47.80 | ▼ −3.06% | ▼ −2.67% | $42.45 (−13.91%) |
Aug 7, 2026 8w ago | Insider Cluster | $49.31 $47.80 | ▼ −3.06% | ▼ −2.67% | $42.45 (−13.91%) |
Aug 5, 2026 8w ago | Insider Cluster | $47.74 $48.37 | ▲ +1.32% | ▲ +1.92% | $42.45 (−11.08%) |
Jul 29, 2026 9w ago | 8-K | $46.04 $48.17 | ▼ −4.63% | ▲ +0.39% | $42.45 (+7.80%) |
Jul 27, 2026 9w ago | 8-K | $46.06 $49.86 | ▲ +8.25% | ▲ +4.87% | $42.45 (−7.84%) |
Jul 27, 2026 9w ago | Court Ruling | $45.51 $49.01 | ▲ +7.69% | ▲ +4.39% | $42.45 (−6.72%) |
Jul 10, 2026 12w ago | Court Ruling | $44.77 $49.30 | ▲ +10.11% | ▲ +7.69% | $42.45 (−5.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access